JP7662639B2 - エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 - Google Patents

エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 Download PDF

Info

Publication number
JP7662639B2
JP7662639B2 JP2022535123A JP2022535123A JP7662639B2 JP 7662639 B2 JP7662639 B2 JP 7662639B2 JP 2022535123 A JP2022535123 A JP 2022535123A JP 2022535123 A JP2022535123 A JP 2022535123A JP 7662639 B2 JP7662639 B2 JP 7662639B2
Authority
JP
Japan
Prior art keywords
cancer
piperidine
methyl
dione
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506155A (ja
JPWO2021118629A5 (https=
JP2023506155A5 (https=
Inventor
ジエ ファン，
イミン チアン，
ウェイ ヘ，
ケ リウ，
Original Assignee
アキュター バイオテクノロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキュター バイオテクノロジー インコーポレイテッド filed Critical アキュター バイオテクノロジー インコーポレイテッド
Publication of JP2023506155A publication Critical patent/JP2023506155A/ja
Publication of JPWO2021118629A5 publication Critical patent/JPWO2021118629A5/ja
Publication of JP2023506155A5 publication Critical patent/JP2023506155A5/ja
Priority to JP2025015907A priority Critical patent/JP2025081364A/ja
Application granted granted Critical
Publication of JP7662639B2 publication Critical patent/JP7662639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022535123A 2019-12-12 2020-04-13 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 Active JP7662639B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015907A JP2025081364A (ja) 2019-12-12 2025-02-03 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947213P 2019-12-12 2019-12-12
US62/947,213 2019-12-12
PCT/US2020/027895 WO2021118629A1 (en) 2019-12-12 2020-04-13 Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015907A Division JP2025081364A (ja) 2019-12-12 2025-02-03 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Publications (4)

Publication Number Publication Date
JP2023506155A JP2023506155A (ja) 2023-02-15
JPWO2021118629A5 JPWO2021118629A5 (https=) 2024-01-29
JP2023506155A5 JP2023506155A5 (https=) 2024-01-29
JP7662639B2 true JP7662639B2 (ja) 2025-04-15

Family

ID=70289288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535123A Active JP7662639B2 (ja) 2019-12-12 2020-04-13 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用
JP2025015907A Pending JP2025081364A (ja) 2019-12-12 2025-02-03 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015907A Pending JP2025081364A (ja) 2019-12-12 2025-02-03 エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Country Status (11)

Country Link
US (2) US10800770B1 (https=)
EP (2) EP3835298B1 (https=)
JP (2) JP7662639B2 (https=)
KR (1) KR102942706B1 (https=)
CN (2) CN115003295B (https=)
CA (1) CA3164202A1 (https=)
DK (1) DK3835298T3 (https=)
ES (1) ES2986594T3 (https=)
FI (1) FI3835298T3 (https=)
MX (1) MX2022007155A (https=)
WO (1) WO2021118629A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081364A (ja) * 2019-12-12 2025-05-27 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021133886A1 (en) * 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CA3169011A1 (en) * 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
EP4289841A4 (en) * 2021-02-04 2025-02-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
WO2022187588A1 (en) * 2021-03-04 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of estrogen receptor with cereblon ligands
MX2023011166A (es) * 2021-03-29 2023-09-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
AU2022370021B2 (en) * 2021-10-22 2026-04-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
CN113816927B (zh) * 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2024015409A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
WO2024153025A1 (zh) * 2023-01-16 2024-07-25 南京明德新药研发有限公司 取代的苯并七元环化合物及其应用
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2025245408A1 (en) 2024-05-22 2025-11-27 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502710A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体
JP2001502711A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―３、４―クロマン誘導体
JP2002154953A (ja) 2000-09-21 2002-05-28 Pfizer Prod Inc エストロゲンアゴニスト／アンタゴニストを用いる骨関節炎の治療方法
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
US20180155322A1 (en) 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) * 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO2003063659A1 (de) 2002-02-01 2003-08-07 Danny Bellens Ablageständer
EP3303326B1 (en) * 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502710A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体
JP2001502711A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―３、４―クロマン誘導体
JP2002154953A (ja) 2000-09-21 2002-05-28 Pfizer Prod Inc エストロゲンアゴニスト／アンタゴニストを用いる骨関節炎の治療方法
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
US20180155322A1 (en) 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081364A (ja) * 2019-12-12 2025-05-27 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用

Also Published As

Publication number Publication date
US20210221802A1 (en) 2021-07-22
FI3835298T3 (fi) 2024-07-29
JP2023506155A (ja) 2023-02-15
MX2022007155A (es) 2022-10-07
CA3164202A1 (en) 2021-06-17
US11261178B2 (en) 2022-03-01
WO2021118629A1 (en) 2021-06-17
DK3835298T3 (da) 2024-07-29
EP4420728A2 (en) 2024-08-28
EP3835298A1 (en) 2021-06-16
CN115003295B (zh) 2025-05-06
KR20220118460A (ko) 2022-08-25
ES2986594T3 (es) 2024-11-12
KR102942706B1 (ko) 2026-03-20
EP4420728A3 (en) 2024-10-30
CN120665056A (zh) 2025-09-19
US10800770B1 (en) 2020-10-13
JP2025081364A (ja) 2025-05-27
EP3835298B1 (en) 2024-06-26
CN115003295A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
JP7662639B2 (ja) エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用
EP3675839B1 (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
JP7307796B2 (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
US11111210B2 (en) Phenyl cyclohexanone derivatives and methods of making and using them
JP2022549222A (ja) アンドロゲン受容体分解活性を有する新規尿素およびその使用
JP2024527577A (ja) ３，４－メチレンジオキシメタンフェタミン及び関連する幻覚剤ならびにその使用
HUE031248T2 (en) New bicyclic pyridinones
WO2018013559A1 (en) Novel compounds and uses thereof
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
HK40080061A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
HK40080061B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
WO2013047719A1 (ja) 2-(ピリジン-2-イル)ピリミジン-4-アミン化合物又はその塩
HK40014926A (en) Novel compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7662639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150